Stock AVIR ATEA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Official Publications Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
3.28 USD +0.92% Intraday chart for Atea Pharmaceuticals, Inc. -2.67% +7.54%
Jun. 05 Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 CI
May. 22 Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 CI

Official Publications

No official publication found

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies
  1. Stock Market
  2. Equities
  3. AVIR Stock
  4. News Atea Pharmaceuticals, Inc.
  5. Official Publications